Skip to content

Quick ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-1.1×
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
4.2×+0.7×
PTC Therapeutics logo
PTC TherapeuticsPTCT
2.4×-1.5×
Insmed logo
InsmedINSM
4.1×-1.3×
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
8.4×+1.9×

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.76B-63.1%

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Calculated from Sarepta Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s quick ratio?
Sarepta Therapeutics, Inc. (SRPT) reported quick ratio of 4.3× in Q1 2026.
How has Sarepta Therapeutics, Inc.'s quick ratio changed year-over-year?
Sarepta Therapeutics, Inc.'s quick ratio increased by 15.0% year-over-year, from 3.7× to 4.3×.
What is the long-term trend for Sarepta Therapeutics, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s quick ratio has grown at a -16.9% compound annual growth rate (CAGR), from 5.4× to 2.1×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.